Amlitelimab matching placebo to test product clinical trials

A Phase 2, randomized, double-blind, placebo-controlled, parallel group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata

This study is testing a new medicine, amlitelimab, for severe alopecia areata. It's looking at how well the medicine helps hair regrow and if it's safe. Some people will get the medicine, and others will get a dummy treatment, to see the real effects.